Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment

Table 2 The changes in DM patients' inflammation parameters.

Parameters	HC	Metformin (months)			Rosiglitazone (months)
		0	1	2	0	2
WBC × 10 ⁹	6.7 ± 0.1	7.3 ± 0.3^b	7.4 ± 0.4	7.5 ± 0.2	7.04 ± 0.5^b	6.8 ± 0.6
PMNLs × 10 ⁹	4.0 ± 0.1	4.6 ± 0.3^b	4.7 ± 0.2	4.9 ± 0.1	4.2 ± 0.4^b	4.4 ± 0.5
PMNL apoptosis (%)	4.0 ± 0.1	12.7 ± 3.4^b	9.5 ± 2.8^{a, b}	6.5 ± 1.0^a	20.4 ± 4.4^b	7.5 ± 1.9^a
Monocytes × 10 ⁹	0.36 ± 0.02	0.44 ± 0.05^b	0.40 ± 0.04^b	0.39 ± 0.04^a	0.49 ± 0.03^b	0.39 ± 0.01^a
Fibrinogen (mg/dl)	304.6 ± 17.6	440.1 ± 25.2^b	471.1 ± 28.8^b	415.9 ± 41.2^{a, b}	400 ± 16.6^b	332.8 ± 8.1^a,b
Albumin (g/dl)	4.6 ± 0.05	4.53 ± 0.1	4.74 ± 0.1	4.7 ± 0.04	4.5 ± 0.1	4.6 ± 0.1
Transferrin (g/dl)	273.2 ± 10.6	274.6 ± 8.4	276.7 ± 7.2	287.9 ± 7.7	264.7 ± 7.6	286.2 ± 8.9
CRP (mg/L)	1.5 ± 0.1	8.3 ± 1.6^b	6.6 ± 1.1^b	5.8 ± 1.5^{a, b}	4.3 ± 0.9^b	1.8 ± 0.2^a,b